Foon K A, Rossio J L, Schroff R W, Wahl S M, Ruscetti F W, Abrams P G, Rager H C, Pickeral S F, Fidler I J
Hybridoma. 1985 Fall;4(3):211-22. doi: 10.1089/hyb.1985.4.211.
We report the successful generation of human T-cell hybridomas that constitutively secrete lymphokines. An acute lymphoblastic leukemia T-cell line, CCRF-H-SB2, free of reverse transcriptase and mycoplasma, was sensitized to hypoxanthine, aminopterin, and thymidine (HAT) by selecting out a mutant deficient in hypoxanthine guanine phosphoribosyl transferase (HGPRT) in 8-azaguanine. Peripheral blood T lymphocytes from normal donors were incubated in vitro with 10 micrograms/ml of concanavalin A for 48 h and subsequently fused with the CCRF-H-SB2 HAT-sensitive cell line. Following 5 weeks in culture, 38 of 440 wells (8.6%) demonstrated hybridoma growth. Supernatants of these cultures were screened for interleukin-2 (IL-2), chemotactic factor, interferon, migration inhibition factor, and macrophage-activating factor activities. Twelve (of 38) hybrids exhibited IL-2 activity, and eight of these were successfully cloned. The highest secreting clone was demonstrated to have mRNA to IL-2 while the parent CCRF-H-SB2 had no detectable mRNA to IL-2. Three hybrid cultures produced chemotactic factor; one was successfully cloned and grown in serum-free medium, where it continued to constitutively produce chemotactic factor as well as IL-2 activity. The chemotactic factor was determined to have the same molecular weight (12,500 daltons) as leukocyte-derived chemotactic factor. Constitutive IL-2 production remained stable for over 12 months. None of the hybridomas tested produced detectable levels of gamma interferon, migration inhibition factor, or macrophage activation factor. Because these T-cell hybridomas produce lymphokines constitutively and this phenotype is stable, they can be an important source of highly purified human lymphokines for clinical and laboratory investigations.
我们报告了组成性分泌淋巴因子的人T细胞杂交瘤的成功产生。一种不含逆转录酶和支原体的急性淋巴细胞白血病T细胞系CCRF-H-SB2,通过在8-氮杂鸟嘌呤中筛选出次黄嘌呤鸟嘌呤磷酸核糖基转移酶(HGPRT)缺陷的突变体,使其对次黄嘌呤、氨基蝶呤和胸腺嘧啶(HAT)敏感。将来自正常供体的外周血T淋巴细胞与10微克/毫升的伴刀豆球蛋白A在体外孵育48小时,随后与CCRF-H-SB2 HAT敏感细胞系融合。培养5周后,440个孔中的38个(8.6%)显示出杂交瘤生长。对这些培养物的上清液进行白细胞介素-2(IL-2)、趋化因子、干扰素、迁移抑制因子和巨噬细胞激活因子活性的筛选。38个杂交瘤中有12个表现出IL-2活性,其中8个成功克隆。分泌量最高的克隆被证明有IL-2的mRNA,而亲本CCRF-H-SB2没有可检测到的IL-2的mRNA。三种杂交培养物产生趋化因子;其中一种成功克隆并在无血清培养基中生长,在该培养基中它继续组成性地产生趋化因子以及IL-2活性。该趋化因子被确定与白细胞来源的趋化因子具有相同的分子量(12,500道尔顿)。组成性IL-2的产生在超过12个月的时间内保持稳定。所测试的杂交瘤均未产生可检测水平的γ干扰素、迁移抑制因子或巨噬细胞激活因子。由于这些T细胞杂交瘤组成性地产生淋巴因子且这种表型稳定,它们可成为用于临床和实验室研究的高度纯化的人淋巴因子的重要来源。